Immuneering (IMRX) Cash from Operations (2020 - 2026)

Immuneering's Cash from Operations history runs 7 years deep, the most recent figure standing at 18433444.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 30.91% year-over-year to 18433444.0 in Q1 2026; TTM through Mar 2026 was 49697401.0, a 7.26% increase from a year earlier, with the FY2025 full-year figure at 45344595.0, up 17.55% from the prior year.
• Cash from Operations eased to 18433444.0 in Q1 2026 per IMRX's latest filing, from 9840598.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 9446124.0 in Q2 2025 and bottomed at 18433444.0 in Q1 2026.
• The 5-year median for Cash from Operations is 11977235.0 (2025), against an average of 12461618.18.
• Across the five-year window, Cash from Operations tumbled 100.02% in 2022 and soared 32.18% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 11748614.0 in 2022, then retreated by 0.23% to 11775201.0 in 2023, then declined by 23.23% to 14510513.0 in 2024, then soared by 32.18% to 9840598.0 in 2025, then sank by 87.32% to 18433444.0 in 2026.
• Per Business Quant, the three latest IMRX Cash from Operations figures stand at 18433444.0 (Q1 2026), 9840598.0 (Q4 2025), and 11977235.0 (Q3 2025).